COMMUNIQUÉS West-GlobeNewswire

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
28/04/2026
Ad hoc announcement pursuant to Art. 53 LR First quarter Net sales declined -5% (cc 1 , -1% USD), as growth drivers were more than offset by US generic erosion Continued strong performance from priority brands including [...]
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
28/04/2026
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist 1 The trial met both weight loss primary [...]
Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026
28/04/2026
Final results of BIRCH multicenter, randomized, open-label Phase 2a proof-of-concept BIRCH trial with 23 patients, conducted in Belgium Final results build on positive second interim results announced in September 2025 [...]
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
28/04/2026
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release AGAMREE® delivers strong growth as global [...]
CORE Soft Tissue Therapy Reports Full Booking Capacity in First Year as Referral Growth Supports South London Expansion
28/04/2026
Photo courtesy of CORE Soft Tissue Therapy LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- CORE Soft Tissue Therapy reports that its East Dulwich clinic reached full booking capacity within its first year of operation, with [...]
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
28/04/2026
Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the [...]
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
28/04/2026
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall [...]
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
28/04/2026
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in [...]
Rapid Nutrition PLC Announces FY2025 Results and 2026 Strategic Outlook
28/04/2026
LONDON, April 27, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company focused on evidence-based nutrition solutions, today announces its audited results for the financial [...]
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
28/04/2026
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
28/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PSMA 1 -targeted [...]
Cellectis présente sa plateforme d’édition épigénétique pour éteindre des gènes sans modifier l’ADN, lors du congrès annuel de l’ASGCT
27/04/2026
NEW YORK, 27 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
InspireMD to Announce First Quarter 2026 Financial Results
27/04/2026
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter [...]
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
27/04/2026
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting [...]
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
27/04/2026
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% [...]
TOMI Environmental Positioned for Accelerated Growth as Robotaxi Market Rapidly Expands
27/04/2026
TOMI Leverages Proprietary SteraMist iHP Technology to Scale Global Fleet Disinfection FREDERICK, Md., April 27, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in [...]
Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting
27/04/2026
- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma - SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology [...]
Addition Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
27/04/2026
“Best of both modalities” approach combines the efficacy, safety and scalability of RNA therapeutics with the multi-year durability of gene therapies Portfolio prioritizes rare, severe, lifelong non-genetic and genetic [...]
Intellia Announces Proposed Public Offering of Common Stock
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]

Pages